Skip to main content
Premium Trial:

Request an Annual Quote

SynapDx Raises $15.4M

NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.

Google Ventures led the round with Foundation Medical Partners also a new investor. Founding investors North Bridge Venture Partners and General Catalyst Partners also participated in the round.

The funding will be used to support Lexington, Mass.-based SynapDx as it develops a blood-based diagnostic test for autism spectrum disorder. The test is designed to help clinicians identify children with autism earlier than can be currently diagnosed.

In conjunction with the financing, Google's Andrew Conrad was appointed to SynapDx's board. Conrad was the chief scientific officer of Laboratory Corporation of America and co-founder of its National Genetics Institute.

In February, LabCorp made a $2 million investment into SynapDx. SynapDx raised $6 million in a Series A1 financing round in December.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.